Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus

Berezin, Alexander A.; Lichtenauer, Michael; Boxhammer, Elke; Stöhr, Eric J.; Berezin, Alexander E.

doi:10.3390/cells11182794

Cited by 13 publications

(6 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discrepancy in the results principally regards its involvement in the inhibition of the adipogenesis process by downregulating PPARγ expression via the induction of Wnt/β-catenin signaling and the divergence between evidence observed in animal models and in humans [37,38,51]. Recent studies have indicated that irisin is a predictive marker of several pathologies, including sarcopenia, atherosclerosis, and heart failure [45,[68][69][70].…”

Section: Discussionmentioning

confidence: 99%

Irisin: A Possible Marker of Adipose Tissue Dysfunction in Obesity

Tomasello

Pitrone

Guarnotta

et al. 2023

IJMS

View full text Add to dashboard Cite

Adipose tissue (AT) secretes pro- and anti-inflammatory cytokines involved in AT homeostasis, including tumor necrosis factor-α (TNFα) and irisin. The functionality of AT is based on a regulated equilibrium between adipogenesis and extracellular matrix (ECM) remodeling. We investigated the contributions of adipose progenitors (ASCs) and adipocytes (AMCs) to TNFα-induced ECM remodeling and a possible implication of irisin in AT impairment in obesity. ASCs and AMCs were exposed to TNFα treatment and nuclear factor–kappa (NF-kB) pathway was investigated: Tissue Inhibitor of Metalloproteinase (TIMP-1), Twist Family Transcription Factor 1 (TWIST-1), and peroxisome proliferator-activated receptor-γ (PPARγ) expression levels were analyzed. The proteolytic activity of matrix metalloproteinases (MMPs) -2 and -9 was analyzed by zymography, and the irisin protein content was measured by ELISA. In inflamed AMCs, a TIMP-1/TWIST-1 imbalance leads to a drop in PPARγ. Adipogenesis and lipid storage ability impairment come with local tissue remodeling due to MMP-9 overactivation. In vitro and ex vivo measurements confirm positive correlations among inflammation, adipose secreting irisin levels, and circulating irisin levels in patients with visceral obesity. Our findings identify the NF-kB downstream effectors as molecular initiators of AT dysfunction and suggest irisin as a possible AT damage and obesity predictive factor.

show abstract

Section: Discussionmentioning

confidence: 99%

Irisin: A Possible Marker of Adipose Tissue Dysfunction in Obesity

Tomasello

Pitrone

Guarnotta

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…On the contrary, acute HF, acute coronary syndrome, and acute myocardial infarction were associated with an increase in irisin levels, which is considered an adaptive factor that reduces endothelial damage by inhibiting inflammatory reactions and suppressing oxidative stress [185][186][187]. A low irisin level was described as an independent predictor of clinical outcomes in HF patients [188,189]. Although patients with HFpEF and AF had significantly lower irisin levels than those without AF [190], the role of irisin in predicting AF-related events, including relapse after electric cardioversion, has not yet been investigated.…”

Section: Irisinmentioning

confidence: 99%

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion

et al. 2023

Self Cite

View full text Add to dashboard Cite

Atrial fibrillation (AF) is associated with atrial remodeling, cardiac dysfunction, and poor clinical outcomes. External direct current electrical cardioversion is a well-developed urgent treatment strategy for patients presenting with recent-onset AF. However, there is a lack of accurate predictive serum biomarkers to identify the risks of AF relapse after electrical cardioversion. We reviewed the currently available data and interpreted the findings of several studies revealing biomarkers for crucial elements in the pathogenesis of AF and affecting cardiac remodeling, fibrosis, inflammation, endothelial dysfunction, oxidative stress, adipose tissue dysfunction, myopathy, and mitochondrial dysfunction. Although there is ample strong evidence that elevated levels of numerous biomarkers (such as natriuretic peptides, C-reactive protein, galectin-3, soluble suppressor tumorigenicity-2, fibroblast growth factor-23, turn-over collagen biomarkers, growth differential factor-15) are associated with AF occurrence, the data obtained in clinical studies seem to be controversial in terms of their predictive ability for post-cardioversion outcomes. Novel circulating biomarkers are needed to elucidate the modality of this approach compared with conventional predictive tools. Conclusions: Biomarker-based strategies for predicting events after AF treatment require extensive investigation in the future, especially in the presence of different gender and variable comorbidity profiles. Perhaps, a multiple biomarker approach exerts more utilization for patients with different forms of AF than single biomarker use.

show abstract

“…Decreased irisin concentrations in T2DM patients are observed in parallel with cardiovascular complications [131][132][133]. They may have some predictive value in heart failure diagnosis [134,135] and be linked to nephropathy [136]. Some interventions, like sitagliptin treatment, increase serum irisin levels in T2DM patients [137].…”

Section: Irisinmentioning

confidence: 99%

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Rentflejsz,

Wojszel

2024

JCM

View full text Add to dashboard Cite

Sarcopenia is a chronic, progressive skeletal muscle disease characterised by low muscle strength and quantity or quality, leading to low physical performance. Patients with type 2 diabetes mellitus (T2DM) are more at risk of sarcopenia than euglycemic individuals. Because of several shared pathways between the two diseases, sarcopenia is also a risk factor for developing T2DM in older patients. Various biomarkers are under investigation as potentially valuable for sarcopenia diagnosis and treatment monitoring. Biomarkers related to sarcopenia can be divided into markers evaluating musculoskeletal status (biomarkers specific to muscle mass, markers of the neuromuscular junction, or myokines) and markers assuming causal factors (adipokines, hormones, and inflammatory markers). This paper reviews the current knowledge about how diabetes and T2DM complications affect potential sarcopenia biomarker concentrations. This review includes markers recently proposed by the expert group of the European Society for the Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) as those that may currently be useful in phase II and III clinical trials of sarcopenia: myostatin (MSTN); follistatin (FST); irisin; brain-derived neurotrophic factor (BDNF); procollagen type III N-terminal peptide (PIIINP; P3NP); sarcopenia index (serum creatinine to serum cystatin C ratio); adiponectin; leptin; insulin-like growth factor-1 (IGF-1); dehydroepiandrosterone sulphate (DHEAS); C-reactive protein (CRP); interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α). A better understanding of factors influencing these biomarkers’ levels, including diabetes and diabetic complications, may lead to designing future studies and implementing results in clinical practice.

show abstract

Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus

Cited by 13 publications

References 61 publications

Irisin: A Possible Marker of Adipose Tissue Dysfunction in Obesity

Irisin: A Possible Marker of Adipose Tissue Dysfunction in Obesity

Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion

Diabetes Mellitus Should Be Considered While Analysing Sarcopenia-Related Biomarkers

Contact Info

Product

Resources

About